Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UKExpands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues3.2 per cent of the Company’s share capital issued to Institut Mérieux at a share price of 407.4p Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023, it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA ('Institut Mérieux').

Oxford Biomedica完成对ABL Europe的收购，巩固了Oxford Biomedica作为全球纯细胞和基因治疗CDMO的地位，该CDMO在欧盟、美国和英国的多个地点具有多病毒载体功能，扩大了Oxford Biomedica为更多客户服务的能力，释放发展能力并增加收入公司股本的3.2%，以407.4p的股价发行给Mérieux研究所，英国牛津——2024年1月29日：牛津生物医学有限公司（LSE:OXB）（“牛津生物医学”或“公司”），一家以质量和创新为主导的细胞和基因治疗CDMO，今天宣布，继2023年9月20日和12月4日的公告之后，它今天完成了从Mérieux研究所（“Mérieux研究所”）收购ABL Europe SAS（“ABL Europe”）。

The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica's position as a world-leading cell and gene therapy CDMO. This strategic move broadens the Company's international development, manufacturing and testing presence, services and capacity by establishing a strong footprint within the European Union with facilities in Lyon and Strasbourg, France.

收购纯粹的欧洲CDMO ABL Europe，加强了牛津生物医学作为世界领先的细胞和基因治疗CDMO的地位。这一战略举措扩大了公司的国际开发、制造和测试业务、服务和能力，在欧盟建立了强大的足迹，并在法国里昂和斯特拉斯堡设有工厂。

In addition, the acquisition increases Oxford Biomedica's capacity in process and analytical development and early-stage manufacturing across Adenovirus, Lentiviral vectors, AAVs and with this acquisition, MVA and Vaccinia. Pursuant to the transaction terms, as previously disclosed, ABL Europe has been acquired for a consideration of €15million, (including the value of €10million of pre-completion cash funding from Institut Mérieux in ABL Europe) in exchange for 3,149,374 new ordinary shares in the Company (representing 3.2 per cent of the Company’s enlarged issued share capital) which have been issued at a price of 407.

此外，此次收购增加了Oxford Biomedica在腺病毒、慢病毒载体、AAV以及MVA和痘苗病毒的过程和分析开发以及早期制造方面的能力。根据交易条款，如前所述，已以1500万欧元的对价收购ABL Europe，（包括ABL Europe Mérieux研究所提供的1000万欧元竣工前现金资金），以换取公司3149374股新普通股（占公司扩大发行股本的3.2%），发行价格为407。